Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Digital health tools

Topic: Risk, prevention and care in population studies

Background The clinical dementia rating (CDR) scale is commonly used to diagnose dementia due to Alzheimer's disease (AD). The sum of boxes of the CDR (CDR-SB) has recently been emphasized and applied to interventional trials for tracing the progression of cognitive impairment (CI) in the early stages of AD. We aimed to study the influence of baseline CDR-SB on disease progression to dementia or reversion to normal cognition (NC). Materials and methods The baseline CDR Results A total of 1,827 participants were analyzed, including 1,258 (68.9%) non-converters, and 569 (31.1%) converters with mean follow-up of 2.1 (range 0.4-5.5) and 1.8 (range 0.3-5.0) years, respectively. Conversion rates increased with increasing CDR-SB scores. Compared to a CDR-SB score of 0, the hazard ratios (HR) for conversion to dementia were 1.51, 1.91, 2.58, 2.13, 3.46, 3.85, 3.19, 5.12, and 5.22 for CDR-SB scores of 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, and ≥4.5, respectively (all p p Conclusion CDR-SB in predementia or very mild dementia (VMD) stages highly predicts progression to dementia or reversion to NC. Therefore, CDR-SB could be a good candidate for tracing the effectiveness of pharmacological and non-pharmacological interventions in populations without dementia.

Key findings

Why it matters

This study found that the sum of boxes of the clinical dementia rating scale in predementia or very mild dementia stages highly predicts progression to dementia or reversion to normal cognition. The authors suggest it could be a good candidate for tracing the effectiveness of interventions in people without dementia.

Study details

How this study scored 54/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 3 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 54 of 100.54 of 100 points earned46 not earned

Published in a peer-reviewed journal. Scored zero for study design and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in aging neuroscience)
Journal's citation record 2 / 4 Frontiers in Aging Neuroscience: journal h-index 174 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 3 / 4 1,827 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 62 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 10.3 citations a year over 6 year(s) since 2022
Impact for its field and year 3 / 6 Cited 7.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 4 other studies in this library
Still being cited 3 / 4 Cited 51 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Pai‐Yi Chiu: h-index 20 (OpenAlex, whole career)
Institution's track record 0 / 3 China Medical University: institution h-index 382 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 7 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 36212036)
Free to read 2 / 2 Free to read
Total 54 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Tzeng, R. C., Yang, Y. W., Hsu, K. C., Chang, H. T., & Chiu, P. Y. (2022). Sum of boxes of the clinical dementia rating scale highly predicts conversion or reversion in predementia stages. Frontiers in aging neuroscience. https://doi.org/10.3389/fnagi.2022.1021792

Vancouver

Tzeng RC, Yang YW, Hsu KC, Chang HT, Chiu PY. Sum of boxes of the clinical dementia rating scale highly predicts conversion or reversion in predementia stages. Frontiers in aging neuroscience. 2022. doi:10.3389/fnagi.2022.1021792. PMID: 36212036.

BibTeX

@article{tzeng2022-36212036,
  author  = {Tzeng, R. C. and Yang, Y. W. and Hsu, K. C. and Chang, H. T. and Chiu, P. Y.},
  title   = {{Sum of boxes of the clinical dementia rating scale highly predicts conversion or reversion in predementia stages}},
  journal = {Frontiers in aging neuroscience},
  year    = {2022},
  doi     = {10.3389/fnagi.2022.1021792},
  pmid    = {36212036},
  url     = {https://doi.org/10.3389/fnagi.2022.1021792}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Digital health tools

Also tagged “prevalence”

1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.

Similar studies

More on Digital health tools

See all studies in Digital health tools →